Ray Kurzweil, the inventor and futurist who spent more than a decade at Google, has joined Subsense, a four year old Palo Alto startup, as a product and vision advisor, Fortune reported on 3 September.1 Fortune 2026-09-03 Kurzweil as product and vision advisor; four year old Palo Alto company; CEO Tetiana Aleksandrova; 27 million raised; nasal nanoparticles plus magnetic coil headset; mice experiments, years away; medical first then consumer; Neuralink comparison; Kurzweil quote on merging the smartphone with the brain. Open source Subsense is building a brain computer interface with no surgery: charged nanoparticles delivered as a nasal spray cross into the brain, bind near neurons, and are read and driven by a magnetic coil headset the company's chief executive describes as a cross between a baseball cap and a bike helmet.1 Fortune 2026-09-03 Kurzweil as product and vision advisor; four year old Palo Alto company; CEO Tetiana Aleksandrova; 27 million raised; nasal nanoparticles plus magnetic coil headset; mice experiments, years away; medical first then consumer; Neuralink comparison; Kurzweil quote on merging the smartphone with the brain. Open source 2 Longevity.Technology 2025-12-11 10 million from Golden Falcon Capital; 17 million seed earlier in 2025; 27 million total; nasal spray nanoparticles crossing the blood brain barrier as transducers; in vivo program; pilot human trials projected 2027; Palo Alto lab; Aleksandrova quote. Open source The company has raised 27 million dollars, most recently 10 million from Golden Falcon Capital in December 2025, is running experiments on mice, and projects pilot human trials in 2027.2 Longevity.Technology 2025-12-11 10 million from Golden Falcon Capital; 17 million seed earlier in 2025; 27 million total; nasal spray nanoparticles crossing the blood brain barrier as transducers; in vivo program; pilot human trials projected 2027; Palo Alto lab; Aleksandrova quote. Open source 3 HIT Consultant 2025-12-11 Use of funds: in vivo biosafety and hardware miniaturization; new Palo Alto facility; scalable platform framing. Open source Our assessment, with high confidence, is that the Kurzweil appointment is a signal to investors and press, not a change in the science; with moderate confidence, that the non invasive route is the right commercial bet even if the specific mechanism fails, because the surgical route caps the market at patients who will accept a skull operation; and with low confidence on whether inhaled nanoparticles can deliver signal quality that competes with implanted electrodes, which no fetched source claims has been shown in animals, let alone people.
What Subsense is trying to do
The existing brain computer interfaces that work, Neuralink's among them, work because electrodes sit against neurons. Neuralink has implanted about a dozen paralyzed patients who now control computers by thought, and each of them had a hole drilled in the skull to get there.1 Fortune 2026-09-03 Kurzweil as product and vision advisor; four year old Palo Alto company; CEO Tetiana Aleksandrova; 27 million raised; nasal nanoparticles plus magnetic coil headset; mice experiments, years away; medical first then consumer; Neuralink comparison; Kurzweil quote on merging the smartphone with the brain. Open source Subsense's proposition is to reach the same neurons from the outside. Biocompatible nanoparticles, sprayed into the nose, cross the blood brain barrier and bind to specific receptors, where they act as transducers: a magnetic field from the headset can make them stimulate nearby neurons, and neural activity can in turn be read back through them.2 Longevity.Technology 2025-12-11 10 million from Golden Falcon Capital; 17 million seed earlier in 2025; 27 million total; nasal spray nanoparticles crossing the blood brain barrier as transducers; in vivo program; pilot human trials projected 2027; Palo Alto lab; Aleksandrova quote. Open source The company pairs the particles with hardware and neural decoding software, and Fortune describes two directions of use, stimulating specific brain areas or reading activity from them.1 Fortune 2026-09-03 Kurzweil as product and vision advisor; four year old Palo Alto company; CEO Tetiana Aleksandrova; 27 million raised; nasal nanoparticles plus magnetic coil headset; mice experiments, years away; medical first then consumer; Neuralink comparison; Kurzweil quote on merging the smartphone with the brain. Open source 2 Longevity.Technology 2025-12-11 10 million from Golden Falcon Capital; 17 million seed earlier in 2025; 27 million total; nasal spray nanoparticles crossing the blood brain barrier as transducers; in vivo program; pilot human trials projected 2027; Palo Alto lab; Aleksandrova quote. Open source
The stage is preclinical. The December 2025 funding went to in vivo biosafety programs and hardware miniaturization at a new laboratory in Palo Alto, the mouse experiments Fortune describes are underway, and chief executive Tetiana Aleksandrova's stated aim is medical use first, with Parkinson's and epilepsy style stimulation as the natural targets for a system that can drive neurons, and a consumer product later.1 Fortune 2026-09-03 Kurzweil as product and vision advisor; four year old Palo Alto company; CEO Tetiana Aleksandrova; 27 million raised; nasal nanoparticles plus magnetic coil headset; mice experiments, years away; medical first then consumer; Neuralink comparison; Kurzweil quote on merging the smartphone with the brain. Open source 3 HIT Consultant 2025-12-11 Use of funds: in vivo biosafety and hardware miniaturization; new Palo Alto facility; scalable platform framing. Open source Availability, if the laboratory work succeeds, is years away by the company's own account.1 Fortune 2026-09-03 Kurzweil as product and vision advisor; four year old Palo Alto company; CEO Tetiana Aleksandrova; 27 million raised; nasal nanoparticles plus magnetic coil headset; mice experiments, years away; medical first then consumer; Neuralink comparison; Kurzweil quote on merging the smartphone with the brain. Open source
Why Kurzweil matters, and why he does not
Kurzweil is the most recognizable proponent of the idea that humans and machines will merge, and his quoted goal for Subsense, to merge the smartphone with the brain, is the thesis he has written books about.1 Fortune 2026-09-03 Kurzweil as product and vision advisor; four year old Palo Alto company; CEO Tetiana Aleksandrova; 27 million raised; nasal nanoparticles plus magnetic coil headset; mice experiments, years away; medical first then consumer; Neuralink comparison; Kurzweil quote on merging the smartphone with the brain. Open source For a company with 27 million dollars in a field where Neuralink has raised hundreds of millions, an advisor of that profile buys attention that money cannot, and the fact that this brief exists is evidence the strategy works.
It changes nothing about whether nanoparticles can read a neuron. Advisory roles do not run experiments, and the technical questions, particle biocompatibility over years, signal to noise through the skull, how many particles reach the right receptors and how long they stay, are answered in mice and then in people, not in announcements.2 Longevity.Technology 2025-12-11 10 million from Golden Falcon Capital; 17 million seed earlier in 2025; 27 million total; nasal spray nanoparticles crossing the blood brain barrier as transducers; in vivo program; pilot human trials projected 2027; Palo Alto lab; Aleksandrova quote. Open source Sourcing caveat: the appointment is reported by one outlet from the company's announcement, and the technical description is the company's own.1 Fortune 2026-09-03 Kurzweil as product and vision advisor; four year old Palo Alto company; CEO Tetiana Aleksandrova; 27 million raised; nasal nanoparticles plus magnetic coil headset; mice experiments, years away; medical first then consumer; Neuralink comparison; Kurzweil quote on merging the smartphone with the brain. Open source
Who gains and who loses
Subsense gains the attention it needs to raise the next round, which for a preclinical device company with a 2027 trial target is the round that matters.2 Longevity.Technology 2025-12-11 10 million from Golden Falcon Capital; 17 million seed earlier in 2025; 27 million total; nasal spray nanoparticles crossing the blood brain barrier as transducers; in vivo program; pilot human trials projected 2027; Palo Alto lab; Aleksandrova quote. Open source Golden Falcon Capital and the seed investors gain a marked up story. Patients who would never accept implant surgery gain a possible path, if a distant one, to neuromodulation without it.3 HIT Consultant 2025-12-11 Use of funds: in vivo biosafety and hardware miniaturization; new Palo Alto facility; scalable platform framing. Open source Kurzweil gains a vehicle for a thesis he has so far only written about.
Neuralink and the other implant companies lose nothing in the clinic, where they are years ahead, but they lose a little of the narrative that surgery is the only serious route.1 Fortune 2026-09-03 Kurzweil as product and vision advisor; four year old Palo Alto company; CEO Tetiana Aleksandrova; 27 million raised; nasal nanoparticles plus magnetic coil headset; mice experiments, years away; medical first then consumer; Neuralink comparison; Kurzweil quote on merging the smartphone with the brain. Open source Investors who fund on names rather than data lose if the mouse results disappoint, which is the normal outcome for a novel delivery mechanism. And the field loses a little credibility every time a nasal spray brain interface is covered as if it were near, so the honest framing Fortune uses, preclinical and years away, matters.1 Fortune 2026-09-03 Kurzweil as product and vision advisor; four year old Palo Alto company; CEO Tetiana Aleksandrova; 27 million raised; nasal nanoparticles plus magnetic coil headset; mice experiments, years away; medical first then consumer; Neuralink comparison; Kurzweil quote on merging the smartphone with the brain. Open source
The counter case
The assessment that this is signal rather than substance could be unfair if Subsense's mouse data, due by the company's own timeline around the end of 2026, shows both reading and stimulation through inhaled particles.2 Longevity.Technology 2025-12-11 10 million from Golden Falcon Capital; 17 million seed earlier in 2025; 27 million total; nasal spray nanoparticles crossing the blood brain barrier as transducers; in vivo program; pilot human trials projected 2027; Palo Alto lab; Aleksandrova quote. Open source That would be a genuine result no matter who advises the company, and it would make the 2027 trial plausible. The assessment that non invasive is the right commercial bet also has a counter: the patients who need brain interfaces most, those with paralysis, have already shown they will accept surgery for a working device, and a lower fidelity non surgical system may serve a market that does not exist yet.1 Fortune 2026-09-03 Kurzweil as product and vision advisor; four year old Palo Alto company; CEO Tetiana Aleksandrova; 27 million raised; nasal nanoparticles plus magnetic coil headset; mice experiments, years away; medical first then consumer; Neuralink comparison; Kurzweil quote on merging the smartphone with the brain. Open source Finally, nanoparticles that cross the blood brain barrier and persist near neurons are a drug as much as a device, and the regulatory path for a magnetically actuated intranasal drug device combination is not one anyone has walked.
What to watch
- Published mouse results. A peer reviewed or preprint report of neural reading and stimulation through intranasal nanoparticles by early 2027 would be the first evidence the mechanism works in a living animal.2 Longevity.Technology 2025-12-11 10 million from Golden Falcon Capital; 17 million seed earlier in 2025; 27 million total; nasal spray nanoparticles crossing the blood brain barrier as transducers; in vivo program; pilot human trials projected 2027; Palo Alto lab; Aleksandrova quote. Open source
- An IND or equivalent filing. A regulatory submission to begin human testing in 2027, as projected, would show the biosafety program passed; no filing by the end of 2027 would mean the timeline has slipped.2 Longevity.Technology 2025-12-11 10 million from Golden Falcon Capital; 17 million seed earlier in 2025; 27 million total; nasal spray nanoparticles crossing the blood brain barrier as transducers; in vivo program; pilot human trials projected 2027; Palo Alto lab; Aleksandrova quote. Open source
- A Series A above 50 million dollars. A round of that size within a year would show the Kurzweil signal converted into capital; a smaller bridge would suggest it did not.3 HIT Consultant 2025-12-11 Use of funds: in vivo biosafety and hardware miniaturization; new Palo Alto facility; scalable platform framing. Open source
- A named clinical indication. Public commitment to Parkinson's, epilepsy or another specific condition for the first trial would move the company from platform pitch to medical program.3 HIT Consultant 2025-12-11 Use of funds: in vivo biosafety and hardware miniaturization; new Palo Alto facility; scalable platform framing. Open source
A famous advisor has joined a company whose product is still being tested on mice. The mice will decide whether the advisor was early or wrong.